30 Nov 2016 – Destiny Pharma CEO appointed to the board of GAMRIF

Dr Bill Love, CEO of Destiny Pharma, has been appointed to the expert advisory board set up by the UK government to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF). Professor Dame Sally Davies, the Chief Medical Officer for England, has appointed a 12-member multi-disciplinary board who will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics